중남미의 T세포치료 시장 예측(-2030년) : 지역별 분석 : 모달리티별, 치료 유형별(CAR T세포치료, T세포 수용체 기반), 적응증별

The South & Central America T cell therapy market was valued at US$ 84.11 million in 2022 and is expected to reach US$ 265.59 million by 2030; it is estimated to grow at a CAGR of 15.5% from 2022 to 2030.

Increasing Number of T-Cell Therapy Approvals Fuels the South & Central America T Cell Therapy Market

Targeted treatment, faster and more efficient recovery, and reduced side effects are among the advantages of t cell therapy. Globally, cell therapies are widely adopted owing to the availability of various approval:

In 2023: Kite, a Gilead Company announced launching operations in Saudi Arabia, Singapore, and Brazil as part of its commercial expansion. Kite has filed regulatory applications for its CAR T-cell therapy products in each of the three nations.

For instance, in June 2022, Bristol Myers Squibb received FDA approval for Breyanzi (lisocabtagene maraleucel), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy, for the treatment of adult patients with large B-cell lymphoma (LBCL).

In February 2022, the US Food and Drug Administration (FDA) approved Yescarta (axicabtagene ciloleucel) CAR T-cell therapy for adult patients with large B-cell lymphoma that is refractory to first line chemoimmunotherapy or that relapses within 12 months of first line chemoimmunotherapy. Yescarta is the first CAR T-cell therapy to receive a National Comprehensive Cancer Network (NCCN) Category 1 recommendation.

In February 2022, the FDA approved ciltacabtagene autoleucel (brand name CARVYKTI) for treating adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

In January 2022, the FDA approved Kimmtrak (tebentafusp-tebn) for treating unresectable or metastatic uveal melanoma patients who are HLA-A*02:01 positive.

In March 2021, Abecma (idecabtagene vicleucel) was approved by the FDA for treating relapsed or refractory multiple myeloma. The treatment is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T-cell immunotherapy indicated for treating adult patients with refractory multiple myeloma.

Therefore, the increasing number of approvals for T-cell therapies is fueling the market growth.

South & Central America T Cell Therapy Market Overview

The South & Central America T-cell therapy market is limited to Brazil as the products are only approved and commercially available in the country. According to the Brazilian Journal of Cancerology, it is estimated that ~704,000 new cases of cancer are expected during 2023-2025. More than 12,000 non-Hodgkin lymphoma (NHL) cases in Brazil are estimated to be diagnosed yearly. The Brazilian Health Regulatory Agency (ANVISA) has approved two CAR T-cell therapies in Brazil: tisagenlecleucel (by Novartis) for pediatric patients and young adults with RR B-cell acute lymphoblastic leukemia (ALL) and adults with relapsed/refractory (RR) diffuse large B-cell lymphoma, and ciltacabtagene autoleucel (cilta-cel) for patients with relapsed/refractory multiple myeloma (RRMM). Moreover, in August 2022, Kite, a Gilead Company, expanded its business by launching operations in Brazil, Singapore, and Saudi Arabia. Kite has submitted regulatory applications for its CAR T-cell therapy products. The rising cases of cancer and lymphoma, and the increasing number of applications and clinical trials for T-cell therapies are expected to boost the demand in the coming years.

South & Central America T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)

South & Central America T Cell Therapy Market Segmentation

The South & Central America T cell therapy market is segmented into modality , therapy type, indication, and country.

Based on modality, the South & Central America T cell therapy market is bifurcated into research and commercialized. The commercialized segment held a larger market share in 2022.

Based on therapy type, the South & Central America T cell therapy market is divided into CAR T-cell therapy and T-cell Receptor (TCR)-based. The CAR T-cell therapy segment held a larger market share in 2022.

Based on indication, the South & Central America T cell therapy market is bifurcated into hematologic malignancies and solid tumors. The hematologic malignancies segment held the largest market share in 2022.

Based on country, the South & Central America T cell therapy market is limited to Brazil. Brazil dominated the South & Central America T cell therapy market share in 2022.

Bristol-Myers Squibb Co, Gilead Sciences Inc, Janssen Global Services LLC, and Novartis AG are some of the leading companies operating in the South & Central America T cell therapy market.

Table Of Contents

1. Introduction

• 1.1 The Insight Partners Research Report Guidance
• 1.2 Market Segmentation

2. Executive Summary

• 2.1 Key Insights
• 2.2 South & Central America T Cell Therapy Market, by Country (US$ Million)

3. Research Methodology

• 3.1 Coverage
• 3.2 Secondary Research
• 3.3 Primary Research

4. South & Central America T Cell Therapy Market - Key Industry Dynamics

• 4.1 Market Drivers:
  • 4.1.1 Growing Burden of Cancer Worldwide
  • 4.1.2 Increasing Number of T-Cell Therapy Approvals
• 4.2 Market Restraints
  • 4.2.1 Side-effects of CAR T-Cell Therapy
• 4.3 Market Opportunities
  • 4.3.1 Growing Investment in T-Cell Therapy
• 4.4 Future Trends
  • 4.4.1 Rising Number of CAR T-Cell Therapies in Clinical Trials
• 4.5 Impact Analysis:

5. T Cell Therapy Market - South & Central America Market Analysis

• 5.1 South & Central America T Cell Therapy Market Revenue (US$ Mn), 2022 - 2030

6. South & Central America T Cell Therapy Market - Revenue and Forecast to 2030 - by Modality.

• 6.1 Overview
• 6.2 South & Central America T Cell Therapy Market Revenue Share, by Modality, 2022 & 2030 (%)
• 6.3 Research
  • 6.3.1 Overview
  • 6.3.2 Research: South & Central America T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
• 6.4 Commercialized
  • 6.4.1 Overview
  • 6.4.2 Commercialized: South & Central America T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)

7. South & Central America T Cell Therapy Market - Revenue and Forecast to 2030 - by Therapy Type

• 7.1 Overview
• 7.2 South & Central America T Cell Therapy Market Revenue Share, by Therapy Type 2022 & 2030 (%)
• 7.3 CAR T-cell Therapy
  • 7.3.1 Overview
  • 7.3.2 CAR T-cell Therapy: South & Central America T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
• 7.4 T-cell Receptor (TCR)-based.
  • 7.4.1 Overview
  • 7.4.2 T-cell Receptor (TCR)-based: South & Central America T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)

8. South & Central America T Cell Therapy Market - Revenue and Forecast to 2030 - by Indication

• 8.1 Overview
• 8.2 South & Central America T Cell Therapy Market Revenue Share, by Indication, 2022 & 2030 (%)
• 8.3 Hematologic Malignancies
  • 8.3.1 Overview
  • 8.3.2 Hematologic Malignancies: South & Central America T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.3.3 South & Central America T Cell Therapy Market , by Haematological Malignancies, 2020-2030 (US$ Million)
• 8.4 Solid Tumor
  • 8.4.1 Overview
  • 8.4.2 Solid Tumor: South & Central America T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)

9. South & Central America T Cell Therapy Market - Country Analysis

• 9.1 Overview
  • 9.1.1 South & Central America T Cell Therapy Market by Country
    • 9.1.1.1 Brazil
      • 9.1.1.1.1 Brazil: South & Central America T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
      • 9.1.1.1.2 Brazil: South & Central America T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
      • 9.1.1.1.3 Brazil: South & Central America T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
      • 9.1.1.1.4 Brazil: South & Central America T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
      • 9.1.1.1.4.1 Brazil: South & Central America T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)

10. T Cell Therapy Market-Industry Landscape

• 10.1 Overview
• 10.2 Growth Strategies in T Cell Therapy Market
• 10.3 Organic Growth Strategies
  • 10.3.1 Overview
• 10.4 Inorganic Growth Strategies
  • 10.4.1 Overview

11. Company Profiles

• 11.1 Janssen Global Services LLC
  • 11.1.1 Key Facts
  • 11.1.2 Business Description
  • 11.1.3 Products and Services
  • 11.1.4 Financial Overview
  • 11.1.5 SWOT Analysis
  • 11.1.6 Key Developments
• 11.2 Gilead Sciences Inc
  • 11.2.1 Key Facts
  • 11.2.2 Business Description
  • 11.2.3 Products and Services
  • 11.2.4 Financial Overview
  • 11.2.5 SWOT Analysis
  • 11.2.6 Key Developments
• 11.3 Bristol-Myers Squibb Co
  • 11.3.1 Key Facts
  • 11.3.2 Business Description
  • 11.3.3 Products and Services
  • 11.3.4 Financial Overview
  • 11.3.5 SWOT Analysis
  • 11.3.6 Key Developments
• 11.4 Novartis AG
  • 11.4.1 Key Facts
  • 11.4.2 Business Description
  • 11.4.3 Products and Services
  • 11.4.4 Financial Overview
  • 11.4.5 SWOT Analysis
  • 11.4.6 Key Developments

12. Appendix

• 12.1 About Us
• 12.2 Glossary of Terms